-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Psoriasis is a chronic, immune- mediated skin disease that affects approximately 2% of the world’s population
.
At present, a variety of systemic targeted and biological therapies have been used for the treatment of moderate to severe psoriasis in adults.
Researchers of
Patients with mild to severe plaque psoriasis participated in the study, including 2 parallel studies
.
The patient’s baseline PGA score is 2 (mild) to 4 (severe, the PGA score ranges from 0 to 4, the higher the score, the more severe the psoriasis symptoms), the patient’s affected skin area accounts for 3% to 20% of the total surface.
Quality of Life
In trial 1 and trial 2, 692 and 674 patients were screened respectively , of which 510 and 515 patients were included in the study
.
In trial 1, 35.
In screening test 1, 35.
PGA response rate increased significantly after Tapinarof treatment
PGA response rate increased significantly after Tapinarof treatmentStudies believe that once a day topical treatment with 1% Tapinarof cream can significantly alleviate the symptoms of patients with plaque psoriasis
.
.
Local treatment with 1% Tapinarof cream once a day can significantly alleviate the symptoms of patients with plaque psoriasis
Original source:
Mark G.
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Leave a message here